As reported on PharmaBiz, ModeX Therapeutics, a clinical-stage biotechnology company within OPKO Health, has begun dosing patients in a first-in-human clinical trial evaluating MDX2003, a next-generation tetra-specific T‑cell engager for the treatment of relapsed or refractory B‑cell lymphomas.
MDX2003 is designed to recognize and bind four distinct immune targets simultaneously. On malignant B cells, the antibody engages both CD19 and CD20 (two widely expressed surface antigens) while also activating T cells through CD3 and the co‑stimulatory receptor CD28. This multi-pronged approach aims to enhance and prolong T‑cell–mediated tumor killing while reducing the risk of tumor escape driven by antigen loss.
The ongoing Phase 1 study, MDX‑2003‑101 (NCT07249905), is enrolling adults with various subtypes of advanced B‑cell lymphoma. The trial includes both dose-escalation and dose-expansion components and is intended to characterize the therapy’s safety profile, tolerability, pharmacokinetics, and immune effects. B‑cell lymphomas make up the majority of non-Hodgkin lymphoma cases, and despite advances in chemoimmunotherapy and cellular therapies, a substantial proportion of patients ultimately develop treatment-resistant disease.
Company leadership highlighted the study as a key developmental milestone. According to ModeX, MDX2003 was engineered to overcome limitations seen with earlier T‑cell engagers by combining dual tumor targeting with optimized co-stimulatory signaling to sustain effective immune responses in heavily pretreated patients. Findings from this early-stage trial are expected to inform dose selection and administration strategies for later efficacy-focused studies.
Preclinical data supporting the clinical advancement of MDX2003 have been shared at major international oncology meetings, including the American Society of Hematology Annual Meeting and the ESMO Targeted Anticancer Therapies Congress. These studies demonstrated potent anti‑tumor activity in lymphoma models alongside controlled T‑cell activation, a balance considered critical for both efficacy and safety.
MDX2003 exemplifies ModeX’s multi-specific antibody platform, which is designed to integrate the functions of several biologics into a single molecule. By simultaneously targeting two B‑cell antigens and providing dual T‑cell activation signals, the therapy seeks to deliver more durable immune pressure against malignant cells.
ModeX Therapeutics is focused on developing multi-specific biologics across oncology, immunology, and infectious diseases. Its parent company, OPKO Health, operates globally across pharmaceutical development and diagnostics, with a strategic emphasis on innovative technologies addressing large and growing medical needs.
